On March 31, 2022 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported the first patient has been dosed by GlaxoSmithKline (GSK) in the Phase 1 study of GSK4381562 in patients with solid tumors (Press release, Surface Oncology, MAR 31, 2022, View Source [SID1234611303]). GSK4381562 is a fully human IgG1 antibody targeting PVRIG, an inhibitory protein expressed on natural killer cells (NK cells) and T cells.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As a result of this Phase 1 initiation, Surface will receive a $30 million milestone payment and is eligible to receive an additional $700 million in potential future milestone payments, as well as tiered royalties on global net sales.
"We are pleased to see GSK4381562 advance into a first-in-human Phase 1 clinical trial and look forward to the valuable insights the study will provide," said Rob Ross, M.D., chief executive officer. "We believe therapies that disrupt the interactions between PVRIG and CD112 can have a meaningful impact on the lives of patients with cancer, and we are excited to support GSK as they advance this novel program into the clinic."
About GSK4381562
GSK4381562 is a fully human, IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells. GSK4381562 binds to a distinct epitope on PVRIG and blocks the interaction of PVRIG with CD112, its binding partner that is overexpressed on tumor cells. Preclinically, GSK4381562 promotes the activation of both NK cells and T cells, with the potential to elicit a strong anti-tumor response and promote immunological memory.